Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

NCT03383575 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Blasts 20-30 Percent of Bone Marrow Nucleated Cells
Chronic Myelomonocytic Leukemia
IDH2 Gene Mutation
Myelodysplastic Syndrome With Excess Blasts
Recurrent High Risk Myelodysplastic Syndrome
Refractory High Risk Myelodysplastic Syndrome

Interventions

DRUG: Azacitidine
DRUG: Enasidenib
OTHER: Quality-of-Life Assessment

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]